Sign in
TerminatedPhase 2

Experimental Study on Alcohol Use and Behavior in Young Adults

Key facts

Who runs it
Karolinska Institutet
Where
Sweden1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
206 people enrolled
Started
17 Oct 2023
Ended
23 Apr 2025
Type of study
Interventional, 4 groups
Treatments tested
  • Oxytocin nasal spray
Record updated
7 May 2025
Why it stopped
Halted due to recruitment problems.

Who can take part

Age
18 years to 24 years
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • 18-24 years of age
  • Male
  • Give informed consent and comply with study procedure
  • Understands written Swedish; Alcohol use disorder (AUD) group
  • Fulfils criteria for at least moderate AUD the past 12 months according to MINI Neuropsychiatric Interview
  • Fulfils at least 8 points on the Alcohol Use Disorder Identification Test; Healthy control group
  • No criteria for AUD the past 12 months according to MINI Neuropsychiatric Interview
  • Fulfils less than 8 points on the Alcohol Use Disorder Identification Test

Who cannot take part

  • Cannabis use on day of testing or day before testing
  • Using non-prescription medicine that could not be stopped 48 hours prior to each visit
  • Using intranasal medicine that could not be stopped 48 hours prior to each visit
  • Fulfils criteria for any substance use disorder (except AUD for AUD-group, and mild cannabis- and nicotine use disorder for both groups)
  • History of severe psychiatric disorder (e.g. severe depression, bipolar, antisocial personality disorder) or neuropsychiatric disorder of ADHD, autism or Tourette's
  • Medical conditions of such severity that they require continual clinical attention, such as regular follow-up visits, prescribed medications or other specific treatment
  • Allergy or intolerance to preservatives in nasal spray, e.g. latex allergy
  • Upper-respiratory tract infection (i.e. a 'common cold' resulting in significant nasal congestion) at day of testing (but with the possibility of rescheduling for another time point)
  • History of nasal disease (e.g. atrophic rhinitis, recurrent nose bleeds), nose damage (e.g. broken nose), and nasal surgery
  • History of head trauma (i.e. loss of consciousness longer than 2 minutes)
  • Using cocaine, amphetamines, hallucinogens, benzodiazepines, etc. within 1 month of the start of the study (excluding cannabis)
  • Cannabis use more than 2 days in past month
  • Traces of alcohol as measured by breathalyzer on the day of testing
  • Prescription medicine the past 3 months
  • Prescription medicine the past 3 months
  • Simultaneous participation in another clinical trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this double blind randomized placebo-controlled clinical trial is to compare intranasal oxytocin and placebo in young adult individuals with alcohol use disorder as compared to healthy controls. The main questions it aims to answer are:

Read full original descriptionShow less

* The effect of oxytocin versus placebo on prosocial behavior in individuals with high- versus low alcohol use * The effect of oxytocin versus placebo on impulsivity, emotion recognition, social learning, and alcohol craving in individuals with high- versus low alcohol use

Participants in both groups will on two separate visits perform the following validated behavioral task measures:

* Dictator game tasks assessing prosocial behavior * Delay discounting task assessing impulsivity * Emotion recognition task assessing emotion recognition * Alcohol cue craving task assessing alcohol craving * Observational fear learning task assessing social learning

Researchers will compare groups of high and low alcohol use to see if there is a difference in effect of oxytocin versus placebo between groups.

The 4 groups in the trial

  • Oxytocin/Placebo, Alcohol Use DisorderTreatment being tested

    Visit 1: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures Visit 2: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures

    Treatment: Oxytocin nasal spray

  • Placebo/Oxytocin, Alcohol Use DisorderTreatment being tested

    Visit 1: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures Visit 2: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures

    Treatment: Oxytocin nasal spray

  • Oxytocin/Placebo, Healthy ControlTreatment being tested

    Visit 1: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures Visit 2: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures

    Treatment: Oxytocin nasal spray

  • Placebo/Oxytocin, Healthy ControlTreatment being tested

    Visit 1: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures Visit 2: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures

    Treatment: Oxytocin nasal spray

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
7 May 2025